News >

Biosimilars Enter US Market, Poised to Impact Cancer Treatment

Ellie Leick
Published: Wednesday, Feb 05, 2020

Adam M. Brufsky, MD, PhD, medical director of the MageeWomen's Cancer Program at the University of Pittsburgh Medical Center Hillman Cancer Center

Adam M. Brufsky, MD, PhD

As biosimilars for bevacizumab (Avastin), rituximab (Rituxan), and trastuzumab (Herceptin) enter clinical practice, patients across a number of cancers will soon likely receive biosimilars rather than originator drugs—a move that will likely be enforced by payers, explained Adam M. Brufsky, MD, PhD, FACP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication